Searchable abstracts of presentations at key conferences in endocrinology

ea0090oc11.4 | Oral Communications 11: Late Breaking | ECE2023

Persistence of mild hypercortisolism in patients with Cushing’s disease treated with cortisol-lowering drugs : the Haircush study

Manon Fafin , Mohammedi Kamel , Bertherat Jerome , Raverot Gerald , DRUI Delphine , Yves Reznik , Castinetti Frederic , Chanson Philippe , Corentin Rouvray , Amandine Galioot , Brossaud Julie , Tabarin Antoine

Background: Medical treatment with cortisol-lowering drugs is commonly used following pituitary surgical failure or recurrence of hypercortisolism in patients with Cushing’s disease (CD). Studies using late-night salivary cortisol (LNSF) measurement have shown persistent disruption of the circadian secretion of cortisol despite normalization of UFC in a subset of medically treated CD patients. Study aim Our objective was to assess the long-term cortisol exposure in CD pat...

ea0090p369 | Diabetes, Obesity, Metabolism and Nutrition | ECE2023

Impact of exenatide on weight loss and eating behavior in adults with craniopharyngioma-related obesity: the Cranioexe randomized placebo-controlled trial

Gatta-Cherifi Blandine , Mohammedi Kamel , Cariou Tanguy , Poitou-Bernert Christine , Touraine Philippe , Raverot Gerald , Brue Thierry , Chanson Philippe , Illouz Frederic , Solange Grunenwald , Chabre Olivier , Sonnet Emmanuel , Cuny Thomas , Bertherat Jerome , Czernichow Sebastien , Frison Eric , Tabarin Antoine

Background: Hyperphagia leading to craniopharyngioma-related obesity (CRO) is a common and serious sequel of treatments of craniopharyngiomas. The few therapeutic approaches that have been tested until now for the control of eating behaviour and weight have poor efficacy. Glucagon-like peptide-1 (GLP-1) analogues might be an option. Methods: This multicentre, randomised, double-blind superiority trial was conducted in France. Adults with CRO (BMI > 3...